Coherus Biosciences (CHRS) PT Lowered to $43 at BMO Capital; 'CHS-1701 CRL Disappointing but Issues Addressable - Buy on Weakness'
Tweet Send to a Friend
BMO Capital lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $43.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
